Elicio Therapeutics Files 8-K
Ticker: ELTX · Form: 8-K · Filed: Jan 22, 2025 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, company-update
Related Tickers: ELIO
TL;DR
ELIO filed an 8-K, something happened. Details TBD.
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on January 22, 2025, reporting an event under 'Other Events'. The company, formerly known as Angion Biomedica Corp. until February 28, 2014, is incorporated in Delaware and headquartered in Boston, Massachusetts. The filing does not disclose specific details of the event.
Why It Matters
This filing indicates a material event has occurred for Elicio Therapeutics, Inc., requiring public disclosure. Investors should monitor for further details to understand the event's implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events', which is broad and could signify significant developments requiring further investigation.
Key Numbers
- 001-39990 — SEC File Number (Identifies the company's filing history)
- 11-3430072 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Former company name
- January 22, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Boston, Massachusetts (location) — Principal executive offices
FAQ
What specific event is being reported under 'Other Events' in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond the general categorization.
When was Elicio Therapeutics, Inc. formerly known as Angion Biomedica Corp.?
Elicio Therapeutics, Inc. was formerly known as Angion Biomedica Corp. until February 28, 2014.
Where are Elicio Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Elicio Therapeutics, Inc. are located at 451 D Street, 5th Floor, Boston, Massachusetts 02210.
What is the SEC file number for Elicio Therapeutics, Inc.?
The SEC file number for Elicio Therapeutics, Inc. is 001-39990.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-22 07:33:06
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Cap
Filing Documents
- angn-20250122.htm (8-K) — 23KB
- fdatypebpr_final.htm (EX-99.1) — 11KB
- fdatypebpr_final001.jpg (GRAPHIC) — 228KB
- fdatypebpr_final002.jpg (GRAPHIC) — 253KB
- fdatypebpr_final003.jpg (GRAPHIC) — 184KB
- 0001601485-25-000006.txt ( ) — 1081KB
- angn-20250122.xsd (EX-101.SCH) — 2KB
- angn-20250122_lab.xml (EX-101.LAB) — 22KB
- angn-20250122_pre.xml (EX-101.PRE) — 13KB
- angn-20250122_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On January 22, 2025, the Company issued a press release announcing that the Company received supportive feedback in an End of Phase 1 Type B meeting with the U.S. Food and Drug Administration regarding the Phase 3 registrational strategy for its ELI-002 product candidate. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated January 22, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: January 22, 2025 Robert Connelly President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)